GlaxoSmithKline Lymerix Cohort Study Adds Two HMOs To Boost Enrollment
GlaxoSmithKline is adding two sites to its Lymerix postmarketing safety study in an effort to increase enrollment in the Phase IV trial.
GlaxoSmithKline is adding two sites to its Lymerix postmarketing safety study in an effort to increase enrollment in the Phase IV trial.